Vol. 2 No. 4 (2022)
Reimbursement Reviews

Pertuzumab (Perjeta)

Published April 27, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses pertuzumab (Perjeta), 420 mg/14 mL vial for IV infusion.
  • Indication: In combination with trastuzumab and chemotherapy for neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either > 2 cm in diameter or node-positive).